Abstract | BACKGROUND: METHODS: RESULTS:
Amlodipine at a dose of 10 mg/day in addition to standard therapy in such patients was associated with no significant difference in change in exercise tolerance on a Naughton protocol compared with placebo in each trial. Among all patients taking amlodipine, exercise time increased 53 +/- 9 (SE) seconds; exercise time for those taking placebo increased 66 +/- 9 seconds (P = not significant). There were no significant differences in changes of quality of life parameters between amlodipine- and placebo-treated patients, and there were no significant differences in symptom scores or New York Heart Association classification between groups. Left ventricular function (measured as ejection fraction) improved 3. 4% +/- 0.5% in amlodipine-treated patients and 1.5% +/- 0.5% in placebo-treated patients (P =.007). There was no statistically significant excess of important adverse events (episodes of worsening heart failure in 10% amlodipine-treated vs 6.3% of placebo-treated patients) or differences in need for changes in background medication between groups. CONCLUSIONS: The addition of 10 mg of amlodipine per day to standard therapy in patients with heart failure is associated with no significant improvement in exercise time compared with placebo therapy over a 12-week period, and there was no increased incidence of adverse events. These data suggest that the addition of amlodipine to standard therapy in heart failure will not result in additional efficacy per se beyond standard therapy.
|
Authors | J E Udelson, C A DeAbate, M Berk, G Neuberg, M Packer, N K Vijay, J Gorwitt, W B Smith, M L Kukin, T LeJemtel, T B Levine, M A Konstam |
Journal | American heart journal
(Am Heart J)
Vol. 139
Issue 3
Pg. 503-10
(Mar 2000)
ISSN: 0002-8703 [Print] United States |
PMID | 10689266
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Calcium Channel Blockers
- Amlodipine
|
Topics |
- Aged
- Amlodipine
(adverse effects, therapeutic use)
- Calcium Channel Blockers
(adverse effects, therapeutic use)
- Double-Blind Method
- Exercise Test
- Exercise Tolerance
(drug effects)
- Female
- Heart Failure
(drug therapy, etiology)
- Hemodynamics
(drug effects)
- Humans
- Male
- Middle Aged
- Quality of Life
- Severity of Illness Index
- Treatment Outcome
- Ventricular Dysfunction, Left
(complications, drug therapy)
- Ventricular Function, Left
(drug effects)
- Walking
|